Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with only three agents…
Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety of…
Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of…
Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to small…
The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…